Resveratrol effect on ventricular and supraventricular arrhythmias

Studying the effect of resveratrol compared to placebo on ventricular and supraventricular arrhythmias in patients with implantable cardiac defibrillators

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120520009801N17

Enrollment

160

Registered

2025-07-18

Start date

2025-08-06

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Re-entry ventricular arrhythmia. Condition 2: Supraventricular tachycardia. Re-entry ventricular arrhythmia Supraventricular tachycardia

Interventions

Intervention 1: Intervention group:Resveratrol capsules 250 mg(RAHA Pharmaceutical Co), one capsule daily for three months. Intervention 2: Control group:Placebo capsule similar to resveratrol capsule

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Age over 18 years Having an ICD for more than 3 months before starting participation in the study Obtaining informed consent from the patient

Exclusion criteria

Exclusion criteria: Taking resveratrol capsules beforehand Severe renal dysfunction(GFR < 30 ml/ min/1.73m2) Significant impairment in liver function (Child-Pugh class B or C). Bleeding disorders Hormone-sensitive conditions such as breast cancer, uterine cancer, ovarian cancer, endometriosis, or uterine fibroids. Taking antioxidant medications Performing major surgeries

Design outcomes

Primary

Measure	Time frame
Ratio of supraventricular and ventricular arrhythmias. Timepoint: At the beginning of the study and 3 months later. Method of measurement: Review of data from implantable cardiac defibrillator devices.	—

Secondary

Measure	Time frame
Shock reduction. Timepoint: Before the start of the study and after 3 months. Method of measurement: Implantable cardiac defibrillator device.;Antitachycardia Pacing (ATP) depletion. Timepoint: Before the start of the study and after 3 months. Method of measurement: Implantable cardiac defibrillator device.;Hospitalization rate. Timepoint: Before the start of the study and after 3 months. Method of measurement: Counting the number of days hospitalized.;Side effects of resveratrol. Timepoint: From the start of the study to 3 months later. Method of measurement: patient monitoring.	—

Measure

Time frame

Shock reduction. Timepoint: Before the start of the study and after 3 months. Method of measurement: Implantable cardiac defibrillator device.;Antitachycardia Pacing (ATP) depletion. Timepoint: Before the start of the study and after 3 months. Method of measurement: Implantable cardiac defibrillator device.;Hospitalization rate. Timepoint: Before the start of the study and after 3 months. Method of measurement: Counting the number of days hospitalized.;Side effects of resveratrol. Timepoint: From the start of the study to 3 months later. Method of measurement: patient monitoring.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmirhooshang Mohamadpoor

Mashhad University of Medical Sciences

MohamadpoorAH@mums.ac.ir+98 51 3180 1592

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026